European Society of Cardiology
Skip navigation links
About the ESC
Guidelines & Surveys
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe

Dyslipidaemias (Management of)

Topics: Cardiovascular Disease Prevention - Risk Assessment and Management


These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention.

Wach the webcast of the joint ESC Guidelines on the Management of  Dyslipidemias presented at the ESC Congress 2011.

Watch the recording of the ESC Webinar on the ESC Guidelines

22/12/2011 00:00:00

Current versions available to download

Publication dateVersionsReferencesSize
2012Essential MessagesEssential Messages Dyslipidaemias557 KB
2011Full TextEuropean Heart Journal (2011) 32, 1769–1818
2011Pocket GuidelinesTable of Contents
2012PdaDownload the PDA version of the Pocket Guidelines
2012 Slide-setESC_Slide_set_on_Dyslipidaemias9 MB
2011CME QuestionsESC/EAS CME Questions Dyslipidaemias
2011Related MaterialsESC/EAS Dyslipidemias addenda2 MB

Current translated versions available to download:


Zeljko Reiner (ESC Chairperson), Alberico L. Catapano (EAS Chairperson), Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund,Stefan Agewall (Norway), Eduardo Alegria (Spain), M. John Chapman (France), Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood (UK).

Declarations of Interest of the experts involved in the elaboration of the document.

Warning Simvastatin

Endorsed by:

Table of Contents

  • 1. Preamble
  • 2. Introduction
  • 3. Total cardiovascular  risk
  • 4. Evaluation of laboratory lipid and apolipoprotein parameters
  • 5. Treatment targets
  • 6. Lifestyle modifications to imporve the plasma lipid profile
  • 7. Drugs for treatment of hypercholesterolaemia
  • 8.Drugs for treatment of hypertriglyceridaemia
  • 9.Drugs affecting high-desity lipoprotein
  • 10.Management of dyslipidaemai in different clinical settings
  • 11.Monitoring of lipids and enzymes in patients on lipid lowering drug therapy
  • 12.How to improve adherence to lifestyle changes and compliance with drug therapy
  • 13.References